TeresaG. Hayes

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
4600 Background: Talactoferrin alfa (formerly known as recombinant human lactoferrin, rhLF) is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties in animal models, and promising early results in patients with advanced renal cell carcinoma (RCC) in Phase 1/2 trials. METHODS An open label Phase 2 study of Talactoferrin Oral(More)
Background:GLIPR1 is upregulated byp53 inprostate cancer cells andhas preclinical antitumor activity. A phase I clinical trial was conducted to evaluate the safety and activity of the neoadjuvant intraprostatic injection of GLIPR1 expressing adenovirus for intermediate or high-risk localized prostate cancer before radical prostatectomy (RP). Methods:(More)
  • 1